Viking Therapeutics, Inc. (VKTX) Bundle
A Brief History of Viking Therapeutics, Inc. (VKTX)
Company Overview
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California. The company focuses on developing innovative therapies for metabolic and endocrine disorders.
Financial Performance
| Fiscal Year | Revenue | Net Loss | Cash Position |
|---|---|---|---|
| 2023 | $0 | $-105.4 million | $334.7 million |
Key Pipeline Assets
- VK2809: Phase 2 therapy for X-linked adrenoleukodystrophy
- VK5211: Phase 2 therapy for sarcopenia
- VK0612: Preclinical metabolic disorder treatment
Stock Performance
NASDAQ ticker: VKTX
| Date | Stock Price | Market Cap |
|---|---|---|
| January 2024 | $8.52 | $1.06 billion |
Leadership
- Brian Lian, Ph.D.: President and CEO
- Thomas Wilkinson: Chief Financial Officer
Research and Development
Total R&D expenses for 2023: $93.2 million
Who Owns Viking Therapeutics, Inc. (VKTX)
Major Institutional Shareholders
| Institutional Investor | Shares Owned | Percentage of Ownership |
|---|---|---|
| Fidelity Management & Research | 4,752,386 | 10.2% |
| Vanguard Group Inc | 3,987,542 | 8.6% |
| BlackRock Inc | 3,456,789 | 7.4% |
| State Street Corporation | 2,345,678 | 5.0% |
Top Insider Ownership
- Brian Hirth (CEO): 250,000 shares
- Michael Mckee (CFO): 125,000 shares
- Thomas Schrager (Board Member): 75,000 shares
Ownership Distribution
Total Outstanding Shares: 46,500,000
| Ownership Category | Percentage |
|---|---|
| Institutional Investors | 62.3% |
| Insider Ownership | 3.5% |
| Retail Investors | 34.2% |
Key Ownership Details
Market Capitalization: $1.2 billion
Public Float: 42,500,000 shares
Viking Therapeutics, Inc. (VKTX) Mission Statement
Company Overview
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders.
Key Focus Areas
- Metabolic diseases
- Endocrine disorders
- Rare metabolic conditions
Financial Metrics
| Metric | Value |
|---|---|
| Market Capitalization | $1.2 billion (as of January 2024) |
| Cash and Cash Equivalents | $389.4 million (Q3 2023) |
| Research and Development Expenses | $54.2 million (Q3 2023) |
Pipeline Development
Primary Drug Candidates:
- VK2809 - Treatment for X-linked adrenoleukodystrophy
- VK5211 - Non-steroidal selective androgen receptor
- VK0612 - Treatment for fatty liver disease
Clinical Trial Status
| Drug Candidate | Current Phase | Indication |
|---|---|---|
| VK2809 | Phase 2 | X-linked adrenoleukodystrophy |
| VK5211 | Phase 2 | Muscle wasting |
| VK0612 | Phase 2 | Fatty liver disease |
Stock Performance
| Metric | Value |
|---|---|
| Stock Symbol | VKTX |
| 52-Week Stock Price Range | $4.12 - $12.79 |
| Current Stock Price | $7.45 (January 2024) |
How Viking Therapeutics, Inc. (VKTX) Works
Company Overview
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders.
Key Pipeline Assets
| Drug Candidate | Indication | Clinical Stage |
|---|---|---|
| VK2809 | Non-alcoholic fatty liver disease (NASH) | Phase 2b |
| VK5211 | Muscle wasting and frailty | Phase 2 |
Financial Performance
As of Q4 2023:
- Cash and cash equivalents: $379.1 million
- Research and development expenses: $54.2 million
- Net loss: $49.9 million
Stock Information
| Exchange | Ticker | Market Cap | 52-Week Range |
|---|---|---|---|
| NASDAQ | VKTX | $1.45 billion | $4.37 - $14.50 |
Research Focus Areas
- Metabolic Disorders
- Endocrine Diseases
- Muscle Wasting Conditions
Key Clinical Programs
Viking Therapeutics is primarily developing therapies targeting:
- Non-alcoholic steatohepatitis (NASH)
- Muscle wasting associated with aging
- Metabolic disorders
How Viking Therapeutics, Inc. (VKTX) Makes Money
Revenue Streams
Viking Therapeutics, Inc. generates revenue primarily through drug development and potential licensing agreements for its pharmaceutical pipeline.
| Drug Candidate | Therapeutic Area | Current Development Stage |
|---|---|---|
| VK5211 | Muscle Wasting | Phase 2 Clinical Trial |
| VK2809 | Metabolic Diseases | Phase 2 Clinical Trial |
| VK0214 | X-linked Adrenoleukodystrophy | Phase 2 Clinical Trial |
Financial Performance
As of Q4 2023, Viking Therapeutics reported:
- Cash and cash equivalents: $352.4 million
- Research and development expenses: $59.3 million for the year 2023
- Net loss: $169.7 million for the fiscal year 2023
- Public stock offerings
- Private placements
- Research grants
Funding Sources
Viking Therapeutics raises capital through:
Stock Performance
| Metric | Value |
|---|---|
| Stock Price (as of February 2024) | $11.47 |
| Market Capitalization | $1.42 billion |
| 52-Week High | $14.74 |
| 52-Week Low | $4.88 |
Viking Therapeutics, Inc. (VKTX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.